This trial will evaluate the safety and clinical activity of a new drug, etavopivat, in patients with thalassemia or sickle cell disease. The goal is to see if the drug can lower the number of red blood cell transfusions required and increase hemoglobin.
- Sickle Cell Disease
3 Primary · 20 Secondary · Reporting Duration: 48 weeks
3 Treatment Groups
Etavopivat 400 mg daily - SCD with transfusions
1 of 3
Etavopivat 400 mg daily - Thalassemia with transfusions
1 of 3
Etavopivat 400 mg daily - Thalassemia
1 of 3
60 Total Participants · 3 Treatment Groups
Primary Treatment: Etavopivat tablets · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 12 - 65 · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is enrollment for this research project still available?
"According to the latest update on clinicaltrials.gov, enrollment for this research is ongoing. This trial was initially advertised in December of 2021 and its details were most recently amended on October 12th 2022." - Anonymous Online Contributor
How many participants are enrolled in this clinical trial at its current capacity?
"This clinical trial requires 60 eligible participants to be recruited. There are a variety of medical sites in which one can partake such as East Carolina University located in Greenville, NC and Children's Hospital Los Angeles situated in LA, CA." - Anonymous Online Contributor
May I partake in this clinical trial?
"In order to be considered for participation in this medical trial, candidates must possess thalassemia and fall between the ages of 12 and 65. Thus far, 60 individuals have been recruited into the study." - Anonymous Online Contributor
Is this research open to elderly individuals aged 75 or more?
"This medical trial is open to participants of 12 years or greater and those under 65." - Anonymous Online Contributor
Are there any potential risks associated with consuming Etavopivat tablets?
"Our team at Power judged the safety of Etavopivat tablets to be a 2, as this is only Phase 2 trial, meaning there exists some evidence for its security but none that it has any beneficial effect." - Anonymous Online Contributor
What is the geographical range of implementation for this trial?
"The trial is being administered at East Carolina University, Children's Hospital Los Angeles, and Weill Medical College of Cornell University in addition to 10 other research sites." - Anonymous Online Contributor